当前位置: X-MOL 学术Nat. Rev. Cardiol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Dapagliflozin for HFrEF - improved outcomes across all ages.
Nature Reviews Cardiology ( IF 49.6 ) Pub Date : 2020-02-01 , DOI: 10.1038/s41569-019-0321-z
Karina Huynh 1
Affiliation  

In two post-hoc analyses of the DAPA-HF trial, the benefits of dapagliflozin were found to be consistent across all age groups and independent of baseline symptom status.

中文翻译:

用于 HFrEF 的 Dapagliflozin - 改善所有年龄段的结果。

在 DAPA-HF 试验的两项事后分析中,发现 dapagliflozin 的益处在所有年龄组中都是一致的,并且与基线症状状态无关。
更新日期:2019-12-04
down
wechat
bug